CD36 and cancer: Despite abundant evidence in mouse models and human tumors that down-regulation of TSR-protein expression by genetic or epigenetic pathways in cancer cells promotes angiogenesis and thereby promotes tumor growth and metastasis, little is known whether modulating TSR interactions with its receptor, CD36, can influence tumor behavior [14]–[17].